Savara Inc
NASDAQ:SVRA
Savara Inc
PP&E Net
Savara Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
PP&E Net
$365k
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
6%
|
|
|
Abbvie Inc
NYSE:ABBV
|
PP&E Net
$5.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
PP&E Net
$5.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
PP&E Net
$6.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
PP&E Net
$2.6B
|
CAGR 3-Years
22%
|
CAGR 5-Years
25%
|
CAGR 10-Years
14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
PP&E Net
$4.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's PP&E Net?
PP&E Net
365k
USD
Based on the financial report for Dec 31, 2024, Savara Inc's PP&E Net amounts to 365k USD.
What is Savara Inc's PP&E Net growth rate?
PP&E Net CAGR 10Y
6%
Over the last year, the PP&E Net growth was -46%. The average annual PP&E Net growth rates for Savara Inc have been -3% over the past three years , -18% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet